Octreotide
Receptors, Somatostatin
Cell surface proteins that bind somatostatin and trigger intracellular changes which influence the behavior of cells. Somatostatin is a hypothalamic hormone, a pancreatic hormone, and a central and peripheral neurotransmitter. Activated somatostatin receptors on pituitary cells inhibit the release of growth hormone; those on endocrine and gastrointestinal cells regulate the absorption and utilization of nutrients; and those on neurons mediate somatostatin's role as a neurotransmitter.
Gastrointestinal Agents
Somatostatin
A 14-amino acid peptide named for its ability to inhibit pituitary GROWTH HORMONE release, also called somatotropin release-inhibiting factor. It is expressed in the central and peripheral nervous systems, the gut, and other organs. SRIF can also inhibit the release of THYROID-STIMULATING HORMONE; PROLACTIN; INSULIN; and GLUCAGON besides acting as a neurotransmitter and neuromodulator. In a number of species including humans, there is an additional form of somatostatin, SRIF-28 with a 14-amino acid extension at the N-terminal.
Acromegaly
A condition caused by prolonged exposure to excessive HUMAN GROWTH HORMONE in adults. It is characterized by bony enlargement of the FACE; lower jaw (PROGNATHISM); hands; FEET; HEAD; and THORAX. The most common etiology is a GROWTH HORMONE-SECRETING PITUITARY ADENOMA. (From Joynt, Clinical Neurology, 1992, Ch36, pp79-80)
Pentetic Acid
Indium Radioisotopes
Carcinoid Tumor
A usually small, slow-growing neoplasm composed of islands of rounded, oxyphilic, or spindle-shaped cells of medium size, with moderately small vesicular nuclei, and covered by intact mucosa with a yellow cut surface. The tumor can occur anywhere in the gastrointestinal tract (and in the lungs and other sites); approximately 90% arise in the appendix. It is now established that these tumors are of neuroendocrine origin and derive from a primitive stem cell. (From Stedman, 25th ed & Holland et al., Cancer Medicine, 3d ed, p1182)
Neuroendocrine Tumors
Tumors whose cells possess secretory granules and originate from the neuroectoderm, i.e., the cells of the ectoblast or epiblast that program the neuroendocrine system. Common properties across most neuroendocrine tumors include ectopic hormone production (often via APUD CELLS), the presence of tumor-associated antigens, and isozyme composition.
Malignant Carcinoid Syndrome
A symptom complex associated with CARCINOID TUMOR and characterized by attacks of severe flushing of the skin, diarrheal watery stools, bronchoconstriction, sudden drops in blood pressure, edema, and ascites. The carcinoid tumors are usually located in the gastrointestinal tract and metastasize to the liver. Symptoms are caused by tumor secretion of serotonin, prostaglandins, and other biologically active substances. Cardiac manifestations constitute CARCINOID HEART DISEASE. (Dorland, 27th ed; Stedman, 25th ed)
Growth Hormone-Secreting Pituitary Adenoma
Pituitary Neoplasms
Neoplasms which arise from or metastasize to the PITUITARY GLAND. The majority of pituitary neoplasms are adenomas, which are divided into non-secreting and secreting forms. Hormone producing forms are further classified by the type of hormone they secrete. Pituitary adenomas may also be characterized by their staining properties (see ADENOMA, BASOPHIL; ADENOMA, ACIDOPHIL; and ADENOMA, CHROMOPHOBE). Pituitary tumors may compress adjacent structures, including the HYPOTHALAMUS, several CRANIAL NERVES, and the OPTIC CHIASM. Chiasmal compression may result in bitemporal HEMIANOPSIA.
Hormones
Chemical substances having a specific regulatory effect on the activity of a certain organ or organs. The term was originally applied to substances secreted by various ENDOCRINE GLANDS and transported in the bloodstream to the target organs. It is sometimes extended to include those substances that are not produced by the endocrine glands but that have similar effects.
Delayed-Action Preparations
Human Growth Hormone
A 191-amino acid polypeptide hormone secreted by the human adenohypophysis (PITUITARY GLAND, ANTERIOR), also known as GH or somatotropin. Synthetic growth hormone, termed somatropin, has replaced the natural form in therapeutic usage such as treatment of dwarfism in children with growth hormone deficiency.
Gallbladder Emptying
Injections, Subcutaneous
Antidiarrheals
Gigantism
The condition of accelerated and excessive GROWTH in children or adolescents who are exposed to excess HUMAN GROWTH HORMONE before the closure of EPIPHYSES. It is usually caused by somatotroph hyperplasia or a GROWTH HORMONE-SECRETING PITUITARY ADENOMA. These patients are of abnormally tall stature, more than 3 standard deviations above normal mean height for age.
Radiopharmaceuticals
Lymphangiectasis, Intestinal
Angiodysplasia
Acquired degenerative dilation or expansion (ectasia) of normal BLOOD VESSELS, often associated with aging. They are isolated, tortuous, thin-walled vessels and sources of bleeding. They occur most often in mucosal capillaries of the GASTROINTESTINAL TRACT leading to GASTROINTESTINAL HEMORRHAGE and ANEMIA.
Carcinoma, Islet Cell
Pancreatic Neoplasms
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
Carcinoid Heart Disease
Cardiac manifestation of gastrointestinal CARCINOID TUMOR that metastasizes to the liver. Substances secreted by the tumor cells, including SEROTONIN, promote fibrous plaque formation in ENDOCARDIUM and its underlying layers. These deposits cause distortion of the TRICUSPID VALVE and the PULMONARY VALVE eventually leading to STENOSIS and valve regurgitation.
Dictionaries as Topic
Electronic Mail
Messages between computer users via COMPUTER COMMUNICATION NETWORKS. This feature duplicates most of the features of paper mail, such as forwarding, multiple copies, and attachments of images and other file types, but with a speed advantage. The term also refers to an individual message sent in this way.
Editorial Policies
Authorship
Postal Service
Internet
Intestinal Obstruction
Bezoars
Intestine, Small
Injections, Intramuscular
Tablets
Wilms Tumor
A malignant kidney tumor, caused by the uncontrolled multiplication of renal stem (blastemal), stromal (STROMAL CELLS), and epithelial (EPITHELIAL CELLS) elements. However, not all three are present in every case. Several genes or chromosomal areas have been associated with Wilms tumor which is usually found in childhood as a firm lump in a child's side or ABDOMEN.
The somatostatin analog octreotide inhibits growth of interleukin-6 (IL-6)-dependent and IL-6-independent human multiple myeloma cell lines. (1/953)
Somatostatin and its analogs can inhibit growth in several cell types, in part by interfering with insulin-like growth factor-I (IGF-I) signaling. Our previous studies point to the importance of paracrine and autocrine IGF-I in the support of growth and survival of human multiple myeloma (MM) cell lines. In this report, we have investigated the potential role of a somatostatin analog, octreotide, in regulating growth and/or survival in MM. The results show that all MM cell lines express functional somatostatin receptors (sst). The MM cell lines express the subtypes sst2, sst3, and predominantly sst5 as determined by reverse-transcriptase polymerase chain reaction and fluorescence-activated cell sorter analysis. Octreotide inhibited the growth of both the interleukin-6 (IL-6)-dependent and the IL-6-independent MM cell lines. The effect is mainly cytostatic, resulting in 25% to 45% growth inhibition, and in three of eight of the MM cell lines a weak induction of apoptosis was recorded. Our results also show that octreotide may act as an inducer of apoptosis in primary B-B4(+) plasma cells isolated from bone marrow of MM patients. In conclusion, the results show a novel pathway for growth inhibition of MM cells: the activation of somatostatin receptor signaling. (+info)In vivo localization of [(111)In]-DTPA-D-Phe1-octreotide to human ovarian tumor xenografts induced to express the somatostatin receptor subtype 2 using an adenoviral vector. (2/953)
Adenoviral vectors, encoding genes for cell surface antigens or receptors, have been used to induce their high level expression on tumor cells in vitro and in vivo. These induced antigens and receptors can then be targeted with radiolabeled antibodies or peptides for potential radiotherapeutic applications. The purpose of this study was to determine a dosing schema of an adenoviral vector encoding the human somatostatin receptor subtype 2 (AdCMVhSSTr2) for achieving the highest tumor localization of [(111)In]-DTPA-D-Phe1-octreotide, which binds to this receptor, in a human ovarian cancer model as a prelude to future therapy studies. AdCMVhSSTr2 was produced and used to induce hSSTr2 on A427 human nonsmall cell lung cancer cells and on SKOV3.ipl human ovarian cancer cells in vitro, as demonstrated by competitive binding assays using [125I]-Tyr1-somatostatin and [(111)In]-DTPA-D-Phe1-octreotide. Mice bearing i.p. SKOV3.ip1 tumors administered 1 x 10(9) plaque-forming units of AdCMVhSSTr2 i.p. 5 days after tumor cell inoculation, followed by an i.p. injection of [(111)In]-DTPA-D-Phe1-octreotide 2 days later, showed a range of 15.3-60.4% median injected dose/gram (ID/g) in tumor at 4 h after injection compared with 3.5% ID/g when [125I]-Tyr1-somatostatin was administered and 0.3% ID/g when the negative control peptide [125I]-mIP-bombesin was administered. Mice administered a control adenoviral vector encoding the gastrin-releasing peptide receptor did not have tumor localization of [(111)In]-DTPA-D-Phe1-octreotide (<1.6% ID/g), demonstrating specificity of [(111)In]-DTPA-D-Phe1-octreotide for the AdCMVhSSTr2 induced tumor cells. In another set of experiments, the tumor localization of [(111)In]-DTPA-D-Phe1-octreotide was not different 1, 2, or 4 days after AdCMVhSSTr2 injection (31.8, 37.7, and 40.7% ID/g, respectively; P = 0.88), indicating that multiple injections of radiolabeled peptide can be administered with equivalent uptake over a 4-day period. [(111)In]-DTPA-D-Phe1-octreotide tumor localization in animals administered AdCMVhSSTr2 on consecutive days or 2 days apart was 22.4% ID/g and 53.2% ID/g, respectively (P = 0.009) when [(111)In]-DTPA-D-Phe1-octreotide was given 1 day after the second AdCMVhSSTr2 injection. There was no difference in [(111)In]-DTPA-D-Phe1-octreotide localization after a single AdCMVhSSTr2 injection (40.7% ID/g) or two injections of AdCMVhSSTr2 given 1 (45.9% ID/g) or 2 (53.2% ID/g) days apart, where [(111)In]-DTPA-D-Phe1-octreotide was given in each case 4 days after the first AdCMVhSSTr2 injection (P = 0.65). Therefore, two AdCMVhSSTr2 injections did not increase [(111)In]-DTPA-D-Phe1-octreotide tumor localization compared with one injection, which eliminates concerns about an immune response to a second dose of AdCMVhSSTr2. This will be the basis for a therapeutic protocol with multiple administrations of an octreotide analogue labeled with a therapeutic radioisotope. (+info)Kleine-Levin and Munchausen syndromes in a patient with recurrent acromegaly. (3/953)
Hypothalamic disease often affects the patients' personality and this also applies to pituitary tumors with suprasellar extension. We report on a patient with a 12-year history of recurrent acromegaly, treated with three transphenoidal operations, single field radiation therapy and bromocriptine/octreotide administration. During the course of follow-up she presented with self-inflicted anemia and Kleine-Levin syndrome (hypersomnia, hyperphagia and hypersexuality). Furthermore, she developed post-radiation necrosis within the right temporal lobe. Whether her neurological and personality disorders result - at least partially - from the acromegaly or the temporal lobe necrosis remains unclear. (+info)Primary hepatic carcinoid in a renal transplant patient. (4/953)
There seems to be a world-wide increase in the incidence of tumors among immunosuppressed patients. Of 1350 renal allografts transplanted in the past 23 years at the Department of Transplantation and Surgery, 56 cases were malignant tumors. The case of a 58-year-old female patient is reported, with disseminated primary carcinoid in the liver detected 86 days after renal transplantation. According to the literature only 39 patients with primary liver carcinoids have been reported until 1997, but this is the first where the carcinoid developed in an immunosuppressed patient. The rapid progression of the carcinoid could be associated with the immunosuppression. (+info)Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. (5/953)
PURPOSE: Subcutaneous (SC) octreotide acetate effectively relieves the diarrhea and flushing associated with carcinoid syndrome but requires long-term multiple injections daily. A microencapsulated long-acting formulation (LAR) of octreotide acetate has been developed for once-monthly intramuscular dosing. PATIENTS AND METHODS: A randomized trial compared double-blinded octreotide LAR at 10, 20, and 30 mg every 4 weeks with open-label SC octreotide every 8 hours for the treatment of carcinoid syndrome. Seventy-nine patients controlled with treatment of SC octreotide 0.3 to 0.9 mg/d whose symptoms returned during a washout period and who returned for at least the week 20 evaluation constituted the efficacy-assessable population. RESULTS: Complete or partial treatment success was comparable in each of the four arms of the study (SC, 58.3%; 10 mg, 66.7%; 20 mg, 71.4%; 30 mg, 61.9%; P> or =.72 for all pairwise comparisons). Control of stool frequency was similar in all treatment groups. Flushing episodes were best controlled in the 20-mg LAR and SC groups; the 10-mg LAR treatment was least effective in the control of flushing. Treatment was well tolerated by patients in all four groups. CONCLUSION: Once octreotide steady-state concentrations are achieved, octreotide LAR controls the symptoms of carcinoid syndrome at least as well as SC octreotide. A starting dose of 20 mg of octreotide LAR is recommended. Supplemental SC octreotide is needed for approximately 2 weeks after initiation of octreotide LAR treatment. Occasional rescue SC injections may be required for possibly 2 to 3 months until steady-state octreotide levels from the LAR formulation are achieved. (+info)Exogenous cysteamine increases basal pancreatic exocrine secretion in the rat. (6/953)
To determine whether exocrine pancreatic secretion is regulated by endogenous somatostatin, somatostatin deficiency was induced by cysteamine. Rats were subcutaneously administered a single dose of cysteamine (30 mg/100 g body weight) 12 hr before experiment. Anesthetized rats were prepared with cannulation into bile duct, pancreatic duct, duodenum, and jugular vein and pancreatic juice was collected. For in vitro study, isolated pancreata of rats, pretreated with cysteamine, were perfused with an intraarterial infusion of Krebs-Henseleit solution (37 degrees C) at 1.2 mL/min, and pancreatic juice was collected in 15-min samples. In vivo experiment of the rat, the mean basal pancreatic secretions, including volume, bicarbonate, and protein output were significantly increased from 18.4+/-0.5 microL/30 min, 0.58+/-0.05 microEq/30 min, and 214.0+/-26.1 microg/30 min to 51.6+/-3.7 microL/30 min, 1.52+/-0.11 microEq/30 min, and 569.8+/-128.9 microg/30 min, respectively (p<0.05). In the isolated perfused pancreas, cysteamine also resulted in a significant increase in basal pancreatic secretion (p<0.05). Simultaneous intraarterial infusion of octreotide (10 pmol/hr) to isolated pancreata partially reversed the effect of cysteamine on basal pancreatic secretion. These findings suggest that endogenous somatostatin play an important role on the regulation of basal pancreatic exocrine secretion. (+info)Expression of somatostatin receptors in oncocytic (Hurthle cell) neoplasia of the thyroid. (7/953)
Ten consecutive patients with Hurthle cell lesions of the thyroid (nodule/adenoma/carcinoma) were studied by (111)In-DTPA-D-Phe1-octreotide scintigraphy. Octreotide scintigraphy localized the primary Hurthle cell tumour in eight patients as distinct areas of increased uptake of radionuclide. Two patients with Hurthle cell carcinoma, previously thyroidectomized, had their metastases visualized by octreotide scintigraphy. Northern analyses showed expression of multiple somatostain receptor subtypes. Visualization of the Hurthle cell tumour may be due to a higher expression of somatostatin receptors in the lesions than in surrounding normal thyroid tissue. The tissue/blood (111)In concentration ratios for tumour samples from five patients showed clearly higher values than observed for normal connective tissue, muscle or lymph nodes. A relatively high uptake of (111)In was also observed in goiter tissue, which may lead to misinterpretations. The main indication for octreotide scintigraphy in patients with Hurthle cell carcinoma is suspicion of metastatic disease. (+info)Somatostatin receptor subtype expression in cells of the rat immune system during adjuvant arthritis. (8/953)
Somatostatin is a neuropeptide that is widely distributed throughout the body. It acts as a neurohormone and a neurotransmitter and may also have an immunomodulatory role. The genes for five subtypes of somatostatin receptors (sst) have been cloned, suggesting that the diverse effects of the peptide might be mediated by different receptors. We are interested in studying the role of sst ininflammation, using an animal model. Because of the up-regulation of sst expression in inflamed joints in human rheumatoid arthritis, we chose rat adjuvant arthritis as an experimental model. In order to determine which of the sst subtypes might be important in immune modulation, subtype expression in leukocytes isolated from different lymphoid tissues of the rat was studied. Also, the expression levels of the most abundantly expressed sst mRNAs in leukocytes from spleen and blood were compared in rats with adjuvantarthritis and controls, using a semi-quantitative approach. Furthermore, the effect of systemic administration of a long-acting somatostatin analogue, octreotide, which binds selectively to sst subtypes 2 and 5 (sst2 and sst5), on the incidence and the severity of rat adjuvant arthritis, was studied. The main sst expressed in cells of the rat immune system, both resting and activated, were found to be sst3 and sst4. This contrasts with the human and murine situations, in which sst2 appears to be the main subtype expressed in the immune system. No quantitative differences in sst subtype mRNA levels in leukocytes from spleen and blood were found between rats with adjuvant arthritis and controls. Finally, no effect of systemic administration of octreotide on either the incidence or severity of adjuvant arthritis in Lewis rats was found. As octreotide binds selectively to sst2 and sst5, the absence of an immunomodulatory effect of this analogue in rat adjuvant arthritis corroborates our finding that these sst subtypes are not expressed in cells of the rat immune system. In conclusion, cells of the rat immune system appear to express a spectrum of sst (sst3 and sst4) different from that found in human granulomatous and autoimmune disease (mainly sst2). Therefore, the rat adjuvant arthritis model appears to be suitable only for studying the immunomodulatory effects of somatostatin analogues which have a high affinity for sst3 and sst4, but not for studying the immunomodulatory effects of octreotide, which has a high affinity only for sst2 and sst5. (+info)
Treatment of hepatocellular carcinoma with long acting somatostatin analogues. - Oxford Clinical Trials Research Unit
Clinical response to the long acting somatostatin analogue SMS 201-995 in a child with congenital microvillus atrophy. | Gut
Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome : final...
Reduction in size of a thyrotropin-secreting pituitary adenoma treated with octreotide acetate (somatostatin analog)<...
Pasireotide LAR and octreotide LAR maintain inhibition of GH and IGF1 in patients with acromegaly: 12-month extension phase of...
Peptide Receptor Radionuclide Therapy: Looking Back, Looking Forward | Bentham Science
Doxorubicin and octreotide induce a 40 kDa breakdown product of p53 in human hepatoma and tumoral colon cell lines |...
The effect of octreotide on gastric emptying at a dosage used to prevent complications after pancreatic surgery: a randomised,...
A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive,...
Peptide receptor radionuclide therapy and NETs: how to select patients?
OPUS Würzburg | Peptide receptor radionuclide therapy as a new tool in treatment-refractory sarcoidosis - initial experience in...
Subcutaneous octreotide treatment of a growth hormone-releasing hormone-secreting bronchial carcinoid: superiority of...
Single center experience of everolimus combined with long-acting octreotide in patients (pts) with pretreated advanced well...
Effective treatment of diabetic diarrhoea with somatostatin analogue, octreotide | Meta
Visual improvement during octreotide therapy in a case of episellar meningioma<...
Octreotide Injection - Octreotide Injection Exporter, Manufacturer, Distributor & Supplier, Mumbai, India
Octreotide injection - Uses, Side Effects, Interactions - Canada.com
SANDOSTATIN® LAR (octreotide acetate for injectable suspension) MAP | Acromegaly
Preoperative octreotide treatment of patients with growth hormone producing pituitary adenomas. - AdisInsight
Effects of the single and combined treatment with dopamine agonist, somatostatin analog and mTOR inhibitors in a human lung...
CAS 83150-76-9 Octreotide Acetate - Hongkong Yuancheng Saichuang Technology Co.,Ltd - ecplaza.net
Chiasma Announces FDA Approval of MYCAPSSA® (Octreotide) Capsules, the First and Only Oral Somatostatin Analog - HealthCare...
Sandostatin (Octreotide Acetate): Uses, Dosage, Side Effects, Interactions, Warning
Sandostatin LAR Inj 30mg 1Vial [IMG 4402 04466 zoom.JPG] - $977.00 : Responsive Sheffield Blue Zen Cart Template, by Picaflor...
Effects of a chronic treatment with octreotide in patients with functionless pituitary adenomas<...
Octreotide Acetate - CCP1356-5mg | acris-antibodies.com
SANDOSTATIN® LAR® (Octreotide) for NET & Acromegaly
Long-Term Follow Up of Thyrotropinomas: The Role of Radiotherapy and Long-Acting Somatostatin Analogs. Report of Two Cases
Can sterile water injections reduce the caesarean section rate? A randomised controlled trial
Plus it
Dr Drugstore: Anac mali pills in stock!
Sandostatin LAR Depot (injection) Uses, Side Effects & Warnings - Drugs.com
Sandostatin LAR Depot vs Somavert Comparison - Drugs.com
Sandostatin LAR 20mg Injection : Uses, Price, Side Effects, Composition, Substitutes, Precautions and Advice - Novartis India...
In vivo release kinetics of octreotide acetate from experimental polymeric microsphere formulations using oil/water and oil/oil...
Find Octreotide acetate (100mg) alternatives online at lowest price in India - PillsBills.com
Comparing the Cost of Treatment with Octreotide Long-Acting Release versus Lanreotide in Patients with Metastatic...
Efficacy of Sandostatin LAR® (octreotide) in clinical studies and trials
Capecitabine and Temozolomide for Neuroendocrine Cancers - Full Text View - ClinicalTrials.gov
Local Drugstore: Viagra commercial actress 16 buy with confidence!
FDA Approves Radiopharmaceutical for Rare Gastrointestinal Cancers - The ASCO Post
FDA Approves Radiopharmaceutical for Rare Gastrointestinal Cancers - The ASCO Post
BeatingCancerCenter - The Di Bella Method - The effects of sandostatin (Octreotide, SMS 201-995) infusion on splanchnic and...
Octreotide - wikidoc
Octapeptide vs Octreotide - Whats the difference? | WikiDiff
Slide S X 13
Buy Sandostatin 0.1mg Injection Online at Lowest Price - DrugsSquare.com
Octreotide for bowel obstruction - Ovarian Cancer - MedHelp
Vital Information About the Sandostatin Lar Depot Kit - D-Liver
Most recent papers with the keyword Skin tumors | Read by QxMD
Radiation precautions for inpatient and outpatient 177 Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine...
FDA approves lutetium Lu 177 dotatate for treatment of GEP-NETS - The Cancer Letter Publications
Pharmacokinetic analysis of [68Ga]Ga-DOTA-TOC PET in meningiomas for assessment of in vivo somatostatin receptor subtype 2 -...
Serum Sodium Concentration in Patients with Portal Hypertension and Acute Gastrointestinal Bleeding Treated with Terlipressin:...
Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-DOTATATE | Journal of Nuclear Medicine
Clinical Trials sub-cluster 63
Pesquisa | Portal Regional da BVS
Postoperative Chylothorax: Is Octreotide A Valid Therapy? | Journal of Case Reports and Studies | Open Access Journals | Annex...
The effects of somatostatin and octreotide on the human sphincter of Oddi - Fingerprint
- Hungarian Consortium
Safety Tolerability and Efficacy of IONIS-GHR-LRx in Patients With Acromegaly Being Treated With Long-acting Somatostatin...
Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors | Oncology | JAMA Surgery |...
Ipsen Presents Data on Somatuline® Depot at the North American Neuroendocrine Tumor Society (NANETS) Annual Symposium - Ipsen US
Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues | A.I.A.N. - Modena
Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly | Clinical Research Trial Listing (...
Browse In Insulin, Patient Demographics | EDM Case Reports
Improving quality of life in patients with pancreatic neuroendocrine tumor following peptide receptor radionuclide therapy...
Sandostatin LAR
-
Anabolic Agents, Hormone replacement
Structure-activity relationship of octreotide analogues labeled with rhenium and technetium-99m
Cancer Treatment Could Target Inflammation In CVD - Redorbit
Australian experience of peptide receptor radionuclide therapy in lung neuroendocrine tumours | Oncotarget
GastroHep News Story
Acromegaly - Pituitary Community South Africa
Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG) - CheckOrphan
Frontiers | Tumor Contrast-Enhancement for Monitoring of PRRT 177Lu-DOTATATE in Pancreatic Neuroendocrine Tumor Patients |...
ENETS Abstract library
ENETS Abstract library
Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant.
carcinoid - meddic
Effect of thalidomide, octreotide, and prednisolone on the migration and proliferation of RPE cells in vitro
Prolactinomas, Cushings disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas | BMC...
Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumors. - PubMed - NCBI
Effects of long term octreotide on gall stone formation and gall bladder function | Garvan Institute of Medical Research
English
Radionuclide Therapy Tied to Neoplasms in Some With Neuroendocrine Tumors
Novartis
Sandostatin (octreotide). Acromegaly. 1,512. 2012[83]. 5%. Signifor (pasireotide) Cushing's disease[87][88] ...
Acromegaly
Octreotide and lanreotide are effective for long-term treatment. Octreotide and lanreotide have also been used successfully to ... In some cases, octreotide treatment can cause diabetes due to the fact that somatostatin and its analogues can inhibit the ... "Octreotide Side Effects". Archived from the original on 22 April 2016. Retrieved 24 July 2019. Lugo G, Pena L, Cordido F (2012 ... The current first choice is generally octreotide or lanreotide; however, bromocriptine and cabergoline are both cheaper and ...
Intestinal pseudo-obstruction
Use of octreotide has been described. Cannabis has long been known to limit or prevent nausea and vomiting from a variety of ... Sørhaug S, Steinshamn SL, Waldum HL (April 2005). "Octreotide treatment for paraneoplastic intestinal pseudo-obstruction ... successfully treated with octreotide". Indian Journal of Medical Sciences. 60 (11): 467-70. doi:10.4103/0019-5359.27974. PMID ...
Lutetium (177Lu) oxodotreotide
Participants were randomly assigned to receive either 177Lu dotatate with long-acting octreotide or long-acting octreotide, at ... 177Lu dotatate was injected through the vein and long-acting octreotide was injected in the muscle. Both, participants and ... All participants received 177Lu dotatate with octreotide. Participants and health care providers knew which treatment was given ... participants had tumors which could not be surgically removed and were worsening while receiving treatment with octreotide. ...
Edotreotide
A phase 2 trial for the use of 90Y DOTA-TOC for patients with metastatic carcinoid, where octreotide treatment was no longer ... "Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors". ClinicalTrials.gov. US National Library ... Edotreotide (USAN, also known as (DOTA0-Phe1-Tyr3)octreotide, or DOTATOC) is a substance which, when bound to various ... April 2010). "90Y-edotreotide for metastatic carcinoid refractory to octreotide". Journal of Clinical Oncology. 28 (10): 1652-9 ...
Necrolytic migratory erythema
Managing the original condition, glucagonoma, by octreotide or surgery. After resection, the rash typically resolves within ...
Midodrine
It is also used with octreotide for hepatorenal syndrome; the proposed mechanism is constriction of splanchnic vessels and ... Karwa, R.; Woodis, C B. (31 March 2009). "Midodrine and Octreotide in Treatment of Cirrhosis-Related Hemodynamic Complications ...
Somatostatin
It is a long-acting analog of somatostatin, like octreotide. It is available in several countries, including the United Kingdom ... Inhibits the release of glucagon Suppresses the exocrine secretory action of the pancreas Octreotide (brand name Sandostatin, ... "In vitro characterization of somatostatin receptors in the human thymus and effects of somatostatin and octreotide on cultured ...
Hypoglycemia
Some forms of congenital hyperinsulinism respond to diazoxide or octreotide. Surgical removal of the overactive part of the ...
Lanreotide
It is a long-acting analogue of somatostatin, like octreotide. Its sequence is H-D-2Nal-Cys(1)-Tyr-D-Trp-Lys-Val-Cys(1)-Thr-NH2 ...
Gastrinoma
Octreotide injections directly release somatostatin hormone that inhibits gastrin release. Chemotherapy. Patients with ...
Octreotate
... or octreotide acid is a somatostatin analogue that is closely related to octreotide. Its amino acid sequence is H-D- ... DOTA-octreotate Laznicek, M.; Laznickova, A.; Mäcke, H. R.; Eisenwiener, K.; Reubi, J. C.; Wenger, S. (2002). "Octreotide and ... Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-OH while octreotide has the terminal threonine reduced to the corresponding amino alcohol. ...
Krwawienie z przewodu pokarmowego, wolna encyklopedia
Somatostatin or octreotide for acute bleeding oesophageal varices. „Cochrane Database Syst Rev", s. CD000193, 2000. DOI: ... Lack of difference among terlipressin, somatostatin, and octreotide in the control of acute gastroesophageal variceal ...
Radiopharmaceutical
In111-Octreotide Somatostatin receptor imaging (Octreoscan) IV In-vivo Imaging Iodine-123Edit. Iodine-123 (I-123) is a gamma ...
Postural orthostatic tachycardia syndrome
... a comparison of octreotide and midodrine". Clinical Autonomic Research. 16 (6): 390-5. doi:10.1007/s10286-006-0373-0. PMID ... "Treatment of Refractory Postural Tachycardia Syndrome with Subcutaneous Octreotide Delivered Using an Insulin Pump". Case ...
Oncogenic osteomalacia
If this scan is not available, other options include Indium-111 Octreotide (Octreoscan) SPECT/CT, whole body CT or MRI imaging ... Some of the tumors express somatostatin receptors and may be located by octreotide scanning. A phosphaturic mesenchymal tumor ... Tumors which secrete somatostatin receptors may respond to treatment with octreotide. If hypophosphatemia persists despite ...
Gastrointestinal bleeding
Octreotide reduces the need for blood transfusions and may decrease mortality. No trials of vitamin K have been conducted. The ... Somatostatin and octreotide, while recommended for varicial bleeding, have not been found to be of general use for non variceal ... Terlipressin appears to be more effective than octreotide, but it is not available in many areas of the world. It is the only ... Medications typically include octreotide or, if not available, vasopressin and nitroglycerin to reduce portal venous pressures ...
Hepatorenal syndrome
January 1999). "Octreotide in the treatment of the hepatorenal syndrome in cirrhotic patients". J. Hepatol. 30 (1): 174. doi: ... Midodrine is an alpha-agonist and octreotide is an analogue of somatostatin, a hormone involved in regulation of blood vessel ... Wong F, Pantea L, Sniderman K (2004). "Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 ... Pomier-Layrargues G, Paquin SC, Hassoun Z, Lafortune M, Tran A (2003). "Octreotide in hepatorenal syndrome: a randomized, ...
Chyle
... as well as by the medications octreotide (a synthetic analogue of the hormone somatostatin) and orlistat (a lipase inhibitor ... "The successful treatment of chylous effusions in malignant disease with octreotide". Clinical Oncology. 17 (2): 118-21. PMID ...
Postural orthostatic tachycardia syndrome
Octreotide[92][93] Hypovolemic POTS Synthetic mineralocorticoid Forces the body to retain salt. Increase blood volume ... a comparison of octreotide and midodrine". Clinical Autonomic Research. 16 (6): 390-5. doi:10.1007/s10286-006-0373-0. PMID ... "Treatment of Refractory Postural Tachycardia Syndrome with Subcutaneous Octreotide Delivered Using an Insulin Pump". Case ...
Vagotomy
"Octreotide therapy of pediatric hypothalamic obesity: a double-blind, placebo-controlled trial". Journal of Clinical ...
Angiodysplasia
... there have been positive reports about octreotide and thalidomide. In severe cases or cases not responsive to either endoscopic ... "Long-term efficacy of octreotide in the prevention of recurrent bleeding from gastrointestinal angiodysplasia". Am. J. ...
Esophageal varices
Terlipressin and octreotide for one to five days have also been used. Caput medusae Esophagitis Gastric varices Mallory-Weiss ... octreotide in bleeding esophageal varices as an adjuvant therapy with endoscopic band ligation: a randomized double-blind ...
Neuroendocrine tumor
Octreotide is a synthetic modifications of somatostatin with a longer half-life.[citation needed] OctreoScan, also called ... to detect larger lesions with tumor cells that are avid for octreotide.[citation needed] Somatostatin receptor imaging can now ... Placebo-controlled prospective randomized study on the antiproliferative efficacy of Octreotide LAR in patients with metastatic ... especially somatostatin analogs such as octreotide.[citation needed] Most gastrointestinal carcinoid tumors tend not to respond ...
Pancreatic fistula
Takeo C, Myojo S (2000). "Marked effect of octreotide acetate in a case of pancreatic pleural effusion". Curr Med Res Opin. 16 ...
Astatine
211At-labeled octreotide Somatostatin receptor 211At-labeled monoclonal antibodies and fragments Various ...
Somatostatin receptor 4
"111In-DTPA-D-Phe1-octreotide binding and somatostatin receptor subtypes in thyroid tumors". Journal of Nuclear Medicine. 41 (4 ... Somatostatin receptor genes expression and effects of octreotide on orbital fibroblasts from Graves' ophthalmopathy]". Minerva ...
Hyperinsulinemic hypoglycemia
... can often be treated with diazoxide or a somatostatin analog called octreotide. Diazoxide is given by mouth, octreotide by ...
Somatostatin receptor 1
"In vitro characterization of somatostatin receptors in the human thymus and effects of somatostatin and octreotide on cultured ... Somatostatin receptor genes expression and effects of octreotide on orbital fibroblasts from Graves' ophthalmopathy]". Minerva ...
Bronchorrhea
Hudson E, Lester J, Attanoos R, Linnane S, Byrne A (2006). "Successful treatment of bronchorrhea with octreotide in a patient ... epidermal growth factor receptor tyrosine kinase inhibitor indomethacin corticosteroids octreotide radiation therapy ...
Octreotide: MedlinePlus Drug Information
Octreotide: learn about side effects, dosage, special precautions, and more on MedlinePlus ... Before taking octreotide,. *tell your doctor and pharmacist if you are allergic to octreotide, any other medications, or any of ... Octreotide may control your symptoms, but it will not cure your condition. Do not stop taking octreotide without talking to ... Octreotide comes as a capsule to take by mouth. It is usually taken twice daily on an empty stomach, at least 1 hour before or ...
Octreotide Injection: MedlinePlus Drug Information
Octreotide Injection: learn about side effects, dosage, special precautions, and more on MedlinePlus ... Continue to use octreotide injection even if you feel well. Do not stop using octreotide injection without talking to your ... Before using octreotide injection,. *tell your doctor and pharmacist if you are allergic to octreotide injection, any other ... Octreotide immediate-release injection is usually injected 2 to 4 times a day. Octreotide long-acting injection is usually ...
Sandostatin LAR (octreotide)
Octreotide is a type of medicine called a somatostatin analogue. It is similar to a naturally-occurring hormone in the body ... Sandostatin LAR is a long-acting depot injection that contains the active ingredient octreotide. ... Other medicines containing octreotide. *Sandostatin short-acting injection.. Octreotide injection is also available without a ... Sandostatin LAR (octreotide). Sandostatin LAR is a long-acting depot injection that contains the active ingredient octreotide. ...
Octreotide - Wikipedia
Octreotide can also be used in the treatment of acromegaly, a disorder of excessive growth hormone (GH). Octreotide, being a ... Octreotide acetate was approved for use in the United States in 1988. In January 2020, approval of octreotide acetate in the ... "Octreotide". Drug Information Portal. U.S. National Library of Medicine. "Octreotide acetate". Drug Information Portal. U.S. ... Some studies reported alopecia in those who were treated by octreotide. Rats which were treated by octreotide experienced ...
Octreotide Medical Definition | Merriam-Webster Medical Dictionary
Medical definition of octreotide: a long-acting synthetic analog of somatostatin that is a cyclic octapeptide, is administered ... Learn More about octreotide. Share octreotide Post the Definition of octreotide to Facebook Share the Definition of octreotide ... Comments on octreotide What made you want to look up octreotide? Please tell us where you read or heard it (including the quote ... Dictionary Entries near octreotide. octopamine octoploid octose octreotide ocular ocularist ocular micrometer ...
Octreotide Acetate Omega - Drugs.com
A list of US medications equivalent to Octreotide Acetate Omega is available on the Drugs.com website. ... Octreotide Acetate Omega is a medicine available in a number of countries worldwide. ... Ingredient matches for Octreotide Acetate Omega. Octreotide. Octreotide acetate (a derivative of Octreotide) is reported as an ... Octreotide Acetate Omega. Octreotide Acetate Omega may be available in the countries listed below. ...
octreotide Tags - SAGES
Octreotide Scan | OncoLink
... an octreotide scan is a non-invasive nuclear medicine test used to evaluate the body for the presence of neuroendocrine tumor ... What is an Octreotide scan?. An octreotide scan, also known as somatostatin receptor scintigraphy, is a test used to check the ... How do I prepare for an octreotide scan?. If you are taking octreotide or somatostatin, you may need to stop the medication ... Obinutuzumab Octreotide Odomzo® Ofatumumab Olanzapine Oral / IM Olaparib Omacetaxine Mepesuccinate Oncaspar Oncovin® ...
Octreotide scan - Wikipedia
A gamma camera detects the radioactive octreotide, and makes pictures showing where the tumor cells are in the body. Octreotide ... An octreotide scan may be used to locate suspected primary neuroendocrine tumours (NET) or for follow-up or staging after ... An octreotide scan is a type of SPECT scintigraphy used to find carcinoid, pancreatic neuroendocrine tumors, and to localize ... Octreotide scan entry in the public domain NCI Dictionary of Cancer Terms This article incorporates public domain material from ...
Octreotide (Professional Patient Advice) - Drugs.com
Professional guide for Octreotide. Includes: pharmacology, pharmacokinetics, contraindications, interactions, adverse reactions ... Although octreotide use is strongly advocated as a first-line therapy, indications and dosing for octreotide are not firmly ... continued octreotide for up to a maximum of 12 months; patients with stable disease continued octreotide and also received ... indications and dosing for octreotide are not firmly established (Glatstein 2012). Octreotide may reduce the incidence of ...
Octreotide and Graves' ophthalmopathy and pretibial myxoedema. | The BMJ
Octreotide for bowel obstruction - Ovarian Cancer - MedHelp
How effective octreotide can be (for treatment and symptomatic relief) in the case of bowel obstruction due to cancer cells ... I have used octreotide alot in my practice. There is along acting form called sandostatin LAR by Novartis. This is a monthly ... Octreotide is one of the agents that can improve the quality of life of women with ovarian cancer. Mostly women who received ... How effective octreotide can be (for treatment and symptomatic relief) in the case of bowel obstruction due to cancer cells ...
Octreotide (Sandostatin®, Sandostatin LAR®) | OncoLink
Octreotide (Sandostatin®, Sandostatin LAR®) is an injectable medication used to treat the symptoms of carcinoid, neuroendocrine ... About: Octreotide (Sandostatin®, Sandostatin LAR®) Octreotide is a hormone that occurs naturally in the body. It is used to ... How to Take Octreotide. The short acting form of octreotide is given as a subcutaneous injection (injection under the skin) or ... Possible Side Effects of Octreotide. There are a number of things you can do to manage the side effects of Octreotide. Talk to ...
Octreotide Acetate - Chemotherapy Drugs - Chemocare
Octreotide Acetate (Sandostatin) hormone therapy side effects, how its given, how it works, precautions and self care tips for ... Other names: Octreotide acetate. Drug type: Octreotide is hormone drug that is used to treat some types of cancer. This ... Octreotide, in contrast, is very stable and, therefore, much longer acting. It is for this reason that octreotide is preferred ... Octreotide has two formulations. For purposes of clarity, trade names will be used for discussion. Sandostatin® is a short ...
DailyMed - OCTREOTIDE ACETATE injection, solution
octreotide 1 MG/ML Injectable Solution. SCD. 14. 312071. octreotide (as octreotide acetate) 1000 MCG/ML Injectable Solution. SY ... octreotide 0.2 MG/ML Injectable Solution. SCD. 17. 314152. octreotide (as octreotide acetate) 200 MCG/ML Injectable Solution. ... octreotide acetate (UNII: 75R0U2568I) (octreotide - UNII:RWM8CCW8GP) octreotide. 50 ug in 1 mL. ... octreotide acetate (UNII: 75R0U2568I) (octreotide - UNII:RWM8CCW8GP) octreotide. 100 ug in 1 mL. ...
Octreotide: uses & side-effects | PatientsLikeMe
Find the most comprehensive real-world treatment information on Octreotide at PatientsLikeMe. 17 patients with fibromyalgia, ... chronic obstructive pulmonary disease or bipolar I disorder currently take Octreotide. ... Currently taking Octreotide Duration. Patients. Percentage. This item is relevant to you: 10 years or more 1 * 100% ... Stopped taking Octreotide Duration. Patients. Percentage. This item is relevant to you: Less than 1 month 1 * 13% ...
DailyMed - OCTREOTIDE- octreotide acetate injection, solution
OCTREOTIDE ACETATE (UNII: 75R0U2568I) (OCTREOTIDE - UNII:RWM8CCW8GP) OCTREOTIDE. 50 ug in 1 mL. ... OCTREOTIDE ACETATE (UNII: 75R0U2568I) (OCTREOTIDE - UNII:RWM8CCW8GP) OCTREOTIDE. 500 ug in 1 mL. ... OCTREOTIDE ACETATE (UNII: 75R0U2568I) (OCTREOTIDE - UNII:RWM8CCW8GP) OCTREOTIDE. 100 ug in 1 mL. ... OCTREOTIDE- octreotide acetate injection, solution. To receive this label RSS feed. Copy the URL below and paste it into your ...
Octreotide Acetate Injection : Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD
Find patient medical information for Octreotide Acetate Injection on WebMD including its uses, side effects and safety, ... octreotide acetate 50 mcg/mL (1 mL) injection syringe. color. clear. shape. No data.. imprint. No data.. This medicine is a ... octreotide acetate 100 mcg/mL (1 mL) injection syringe. color. clear. shape. No data.. imprint. No data.. This medicine is a ... octreotide acetate 500 mcg/mL (1 mL) injection syringe. color. clear. shape. No data.. imprint. No data.. This medicine is a ...
Sandostatin (Octreotide Acetate): Uses, Dosage, Side Effects, Interactions, Warning
Octreotide Acetate) may treat, side effects, dosage, drug interactions, warnings, patient labeling, reviews, and related ... Sandostatin is not compatible in Total Parenteral Nutrition (TPN) solutions because of the formation of a glycosyl octreotide ... Sandostatin® (octreotide acetate) Injection is available in 1 mL ampuls and 5-mL multi-dose vials as follows:. Ampuls. 50 mcg/ ... The elimination of octreotide from plasma had an apparent half-life of 1.7 to 1.9 hours compared with 1-3 minutes with the ...
PatientsLikeMe | Octreotide report for patients like you
Find the most comprehensive real-world treatment information on Octreotide at PatientsLikeMe. 16 patients with fibromyalgia, ... bipolar I disorder or psoriasis currently take Octreotide. ... Currently taking Octreotide Duration. Patients. This item is ... Stopped taking Octreotide Duration. Patients. This item is relevant to you: Less than 1 month 1 * 1 ... Why patients stopped taking Octreotide. Multiple reasons could be selected. Reason. Patients. This item is relevant to you: ...
Mycapssa (Octreotide Oral Capsules): Uses, Dosage, Side Effects, Interactions, Warning
Octreotide Oral Capsules) may treat, side effects, dosage, drug interactions, warnings, patient labeling, reviews, and related ... Each capsule contains 20 mg of octreotide (provided as octreotide acetate). Octreotide is present as a salt with 1.4 to 2.5 ... 20 mg octreotide acetate), and a single dose of subcutaneous Sandostatin IR (0.1 mg octreotide acetate). Peak octreotide levels ... Each capsule contains 20 mg octreotide, provided as octreotide acetate.. Storage And Handling. MYCAPSSA delayed-release 20 mg ...
Genfastat (Octreotide) Genfa Medica
octreotide | healthdirect
Octreotide | Springer for Research & Development
Octreotide injection - Uses, Side Effects, Interactions - MedBroadcast.com
Octreotide is a man-made (synthetic) version of a naturally occurring hormone known as somatostatin. Octreotide is used to ... 02299437 OCTREOTIDE 100µG/ML Injection. 02299445 OCTREOTIDE 200µG/ML Injection. 02299453 OCTREOTIDE 500µG/ML Injection. ... Octreotide should not be used by anyone who is allergic to octreotide or to any of the ingredients of the medication. ... Octreotide is a man-made (synthetic) version of a naturally occurring hormone known as somatostatin. Octreotide is used to ...
Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor - Study Results - ClinicalTrials.gov
Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor (RADIANT-2). The safety and scientific validity of this ... Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3 ... Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with ... Everolimus was administered in accordance with a 10-mg daily dosing regimen (two 5-mg tablets) in conjunction with octreotide ...
Octreotide for the Treatment of Sulfonylurea-Associated Hypoglycemia - Full Text View - ClinicalTrials.gov
mean glucose level for the non-octreotide group is higher than the octreotide group. ... Octreotide for the Treatment of Sulfonylurea-Associated Hypoglycemia. The safety and scientific validity of this study is the ... Octreotide is thought to block the elevated insulin levels that are a result of both the sulfonlyureas and dextrose. Recent ... Comparison of Octreotide and Standard Therapy vs. Standard Therapy Alone for the Treatment of Hypoglycemia in Patients Taking ...
Octreotide (Injection Route, Intramuscular Route, Subcutaneous Route) Description and Brand Names - Mayo Clinic
Octreotide injection is also used to treat a condition called acromegaly, which is caused by too much growth hormone in the ... Octreotide injection is used to treat severe diarrhea and other symptoms that occur with certain intestinal tumors or ... Octreotide works by reducing the amount of growth hormone that is produced by the body. ...
Visual improvement during octreotide therapy in a case of episellar meningioma
Oral Octreotide Found Safe and Effective for Acromegaly in Investigational Study
The findings suggest that people who respond well to oral octreotide would be able to avoid the burden of injections if the ... An investigational oral form of octreotide was safe and effective for the treatment of acromegaly, a rare hormonal disorder, in ... Side Effects of Oral Octreotide Were Similar to Injectable Octreotide Approximately, 89% of patients experienced an adverse ... "Oral octreotide may not work for me, but it may help 10 other people," Ms Sisco said. "When you are dealing with a rare disease ...
AcromegalyInjectionSandostatin LAROral octreotideSubcutaneouslyEffect of OctreotideEffects of octreotideReceive octreotideGrowth hormoneTherapeuticPeptideStarting octreotide treatmentSomatostatin analog octreotideSecretionAnalogForm of octreotideRole of octreotideEfficacy of octreotideAdministration of octreotide0.05Neuroendocrine tumoursInjectableInterventionCyclicMicrogramsHepaticFormulationIntramuscularlyTreatment with octreotide acetateDepotIntestinalDiarrheaScintigraphySymptomsClinicalDosesLanreotideCarcinoid tumorsPancreaticHormonesGastrointestinalMicrospheresShort-acting octAction of octreotideProfile of octreotideSafety and tolerabilitySuggest that octreotideInjections of octreotideTumourInsulinAnalogs
Acromegaly42
- You may be able to become pregnant during your treatment with octreotide even if you were not able to become pregnant before your treatment because you have acromegaly. (medlineplus.gov)
- Octreotide long-acting injection is used to control acromegaly, carcinoid tumors, and VIP-omas in people who have been successfully treated with octreotide injection but prefer to receive injections less often. (medlineplus.gov)
- If you have acromegaly and have been treated with radiation therapy, your doctor will probably tell you not to use octreotide immediate-release injection for 4 weeks every year or not to receive the octreotide long-acting injection for 8 weeks every year. (medlineplus.gov)
- Octreotide is also used to treat acromegaly, which is a condition characterised by enlarged facial features, hands and feet. (netdoctor.co.uk)
- Octreotide is used for the treatment of growth hormone producing tumors (acromegaly and gigantism), when surgery is contraindicated, pituitary tumors that secrete thyroid-stimulating hormone (thyrotropinoma),[citation needed] diarrhea and flushing episodes associated with carcinoid syndrome, and diarrhea in people with vasoactive intestinal peptide-secreting tumors (VIPomas). (wikipedia.org)
- Octreotide can also be used in the treatment of acromegaly, a disorder of excessive growth hormone (GH). (wikipedia.org)
- In June 2020, Mycapssa (octreotide) was approved for medical use in the United States with an indication for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. (wikipedia.org)
- The Food and Drug Administration (FDA) has approved the usage of a salt form of this peptide, octreotide acetate, as an injectable depot formulation for the treatment of acromegaly, the treatment of diarrhea and flushing episodes associated with carcinoid syndrome, and treatment of diarrhea in patients with vasoactive intestinal peptide-secreting tumors (VIPomas). (medhelp.org)
- Octreotide acetate substantially reduces growth hormone and/or IGF-I (somatomedin C) levels in patients with acromegaly. (nih.gov)
- Octreotide is also used to treat a certain condition ( acromegaly ) that occurs when the body makes too much of a certain natural substance called growth hormone . (webmd.com)
- Sandostatin® (octreotide acetate) is indicated to reduce blood levels of growth hormone and IGF-I (somatomedin C) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection , pituitary irradiation , and bromocriptine mesylate at maximally tolerated doses. (rxlist.com)
- Mycapssa (octreotide) is a somatostatin analog indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. (rxlist.com)
- Octreotide also reduces the amount of growth hormone in the body, and so it is also used to treat acromegaly , a condition associated with overgrowth of the hands, feet, and parts of the face. (medbroadcast.com)
- Octreotide injection is also used to treat a condition called acromegaly, which is caused by too much growth hormone in the body. (mayoclinic.org)
- An investigational oral form of octreotide was safe and effective for the treatment of acromegaly , a rare hormonal disorder, in a recent study. (endocrineweb.com)
- The phase 3 trial was designed to see whether people with acromegaly were able to maintain a good response to treatment when switched from their injectable medications to oral octreotide. (endocrineweb.com)
- For people who responded to oral octreotide, the severity and frequency of acromegaly symptoms improved, compared to when patients took injectable medications. (endocrineweb.com)
- These side effects are similar to those for injectable octreotide or are consistent with symptoms of acromegaly. (endocrineweb.com)
- Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial. (endocrineweb.com)
- An investigational oral formulation of octreotide was found to be safe and effective in the treatment of acromegaly in a phase 3 open-label study published online ahead of print in the Journal of Clinical Endocrinology & Metabolism . (endocrineweb.com)
- The most common adverse events (AEs) reported were gastrointestinal (nausea, diarrhea and abdominal pain), neurological, and musculoskeletal, consistent with the known safety profile of octreotide and the disease burden of acromegaly. (endocrineweb.com)
- Octreotide-MaxRx Injection is used to treat acromegaly. (nps.org.au)
- In a recent phase 3 trial, oral octreotide capsules demonstrated sustained biochemical response up to 13 months in patients with acromegaly previously managed with somatostatin analog injections (ref). (centerwatch.com)
- This will be a phase 3, randomized, open-label, active controlled, multicenter study to evaluate maintenance of response, safety and patient reported outcomes (PROs) in acromegaly patients treated with octreotide capsules and in patients treated with SOC parenteral SRLs, who previously tolerated and demonstrated biochemical control on both treatments. (centerwatch.com)
- Patients whose acromegaly is been controlled biochemically on octreotide capsules at the end of the Run-in Phase will enter a 36-week open-label Randomized Controlled Treatment Phase, where they will be randomized to continue on octreotide capsules or switch back to their injectable SRL treatment (as received prior to Screening). (centerwatch.com)
- Octreotide(Sandostatin) generic Sandostatin LAR is a synthetic octapeptide, prescribed for acromegaly. (medindia.net)
- DP1038 (octreotide acetate for intranasal administration) is being developed via the 505(b)(2) regulatory pathway for the treatment of acromegaly and neuroendocrine tumors. (medindia.net)
- What the FDA's complete response letter (CRL) for Mycapssa ( octreotide capsules) to treat adult patients with acromegaly might mean for the ongoing European study remained unclear, as Chiasma Inc. is "revisiting all priorities" and preparing for a post-review meeting with U.S. regulators, said CEO Mark Leuchtenberger. (bioworld.com)
- SAN JOSE, Calif., Jan. 30, 2020 /PRNewswire/ -- Rani Therapeutics , the leader in oral biologics, has today announced positive results from the Phase I clinical study of its orally-delivered version of octreotide, Octreotide-RP, a drug used in the treatment of acromegaly and neuroendocrine tumors. (pharmiweb.com)
- By providing an oral alternative like Octreotide-RP, Rani Therapeutics is making therapy easier and painless for patients, a welcome change for acromegaly and neuroendocrine tumor patients," said Dr. Shlomo Melmed, Executive Vice President of Academic Affairs, Dean of the Medical Faculty and Professor of Medicine at Cedars Sinai. (pharmiweb.com)
- Octreotide has been widely used in the treatment of acromegaly. (ovid.com)
- Swiss drugmaker Roche has struck a $595 million (£390 million) deal with US firm Chiasma for Octreolin (octreotide) tablets for treating acromegaly, a rare condition that causes excessive growth. (chemistryworld.com)
- Octreotide is clinically used for the treatment of esophageal varices caused by portal hypertension, acromegaly, gastrointestinal bleeding including cirrhosis, esophageal varices bleeding, peptic ulcer bleeding and stress ulcer bleeding, pancreatic diseases including heavy acute pancreatitis, pancreatic trauma, or pancreatic fistula after surgery, and prevention of complications after pancreas surgery. (chemicalbook.com)
- Currently approved octreotide products are used for the treatment of several serious disorders, including acromegaly and certain neuroendocrine tumours, and the market for immediate release liquid formulations is estimated to be in excess of $150 million. (fiercepharma.com)
- Approximately half of patients with acromegaly do not respond to treatment with somatostatin receptor ligands such as octreotide LAR. (checkorphan.org)
- Ultrasound guidance of IM injections may improve accuracy of placement of IM injections and increase drug levels, thereby improving efficacy of octreotide LAR for the treatment of acromegaly. (checkorphan.org)
- The purpose of this study is to determine whether octreotide LAR drug levels differ if given by ultrasound-guided IM injection or by regular IM injection in patients with acromegaly. (checkorphan.org)
- STUDY OBJECTIVE: To determine the efficacy of stepwise incremental doses, to compare twice- with thrice-daily administration of the same total daily dosage of the long-acting somatostatin analog SMS 201-995 (octreotide, Sandoz Australia, Sydney, Australia), and to evaluate the risk for cholelithiasis after long-term therapy for acromegaly. (garvan.org.au)
- Octreotide is effective and can be considered as a first-line therapy in patients with acromegaly with mean pretherapy GH concentrations below 20 mIU/L. In patients with mean GH over 20 mIU/L, octreotide may be used as an adjuvant to surgery or radiotherapy. (garvan.org.au)
- Midatech Pharma PLC (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products for rare diseases in oncology and immunotherapy, today announces interim data from the 'first-in-human' study of MTD201 Q-Octreotide, a sustained-release treatment for carcinoid cancer and acromegaly. (apnews.com)
- Octreotide is a somatostatin analogue that is FDA approved for the treatment of acromegaly , severe diarrhea / flushing episodes associated with metastatic carcinoid tumors , profuse watery diarrhea associated with VIP-secreting tumors . (wikidoc.org)
- OCTREOTIDE (ok TREE oh tide) is used to reduce blood levels of growth hormone in patients with a condition called acromegaly. (covenanthealth.com)
Injection54
- and other symptoms) in people who have been treated successfully with octreotide injection (Sandostatin) or lanreotide injection (Somatuline). (medlineplus.gov)
- Octreotide injection is in a class of medications called octapeptides. (medlineplus.gov)
- Octreotide comes as an immediate-release solution (liquid) for injection to be injected subcutaneously (under the skin) or intravenously (into a vein) Octreotide also comes as a long-acting injection to be injected into the muscles of the buttocks by a doctor or nurse. (medlineplus.gov)
- Octreotide immediate-release injection is usually injected 2 to 4 times a day. (medlineplus.gov)
- Octreotide long-acting injection is usually injected once every 4 weeks. (medlineplus.gov)
- Inject octreotide immediate-release injection at around the same times every day. (medlineplus.gov)
- Inject octreotide injection exactly as directed. (medlineplus.gov)
- If you are not already being treated with octreotide injection, you will begin your treatment with immediate-release octreotide injection. (medlineplus.gov)
- Octreotide immediate-release injection comes in vials, ampules, and dosing pens that contain cartridges of medication. (medlineplus.gov)
- These instructions describe how to inject a dose of octreotide injection. (medlineplus.gov)
- Sandostatin LAR is a long-acting depot injection that contains the active ingredient octreotide. (netdoctor.co.uk)
- Sandostatin LAR is a long-acting depot injection of octreotide that is given into the muscle of the buttock (intragluteal) every four weeks by your doctor. (netdoctor.co.uk)
- An IV is placed and an injection of octreotide with radioactive material attached to it (called "radiolabeled"), is given. (oncolink.org)
- About 4 hours after the injection, the patient will undergo a scan to look for cells that have taken up the octreotide. (oncolink.org)
- Limitations of use: The effects of octreotide (injection solution and LAR depot suspension) on tumor size, rate of growth, and development of metastases in patients with carcinoid syndrome and VIPomas have not been determined. (drugs.com)
- The short acting form of octreotide is given as a subcutaneous injection (injection under the skin) or in an intravenous (IV) form. (oncolink.org)
- Octreotide acetate injection, a cyclic octapeptide prepared as a clear sterile solution of octreotide, acetate salt, in a buffered acetate solution with a pH range 3.9 to 4.5 for administration by deep subcutaneous (intrafat) or intravenous injection. (nih.gov)
- Octreotide acetate injection is available as: sterile 1 mL single dose vials in 3 strengths, containing 50, 100 or 500 mcg octreotide (as acetate), and sterile 5 mL multi-dose vials in 2 strengths, containing 200 and 1,000 mcg per mL of octreotide (as acetate). (nih.gov)
- After subcutaneous injection, octreotide is absorbed rapidly and completely from the injection site. (nih.gov)
- Octreotide Acetate Injection, a cyclic octapeptide prepared as a clear sterile solution of octreotide, acetate salt, in a buffered acetate solution for administration by deep subcutaneous (intrafat) or intravenous injection. (nih.gov)
- Octreotide injection is used to treat severe diarrhea and other symptoms that occur with certain intestinal tumors or metastatic carcinoid tumors (tumors that has already spread in the body). (mayoclinic.org)
- I know people who are on the long-acting octreotide and, at the end of the monthly cycle, have to supplement it with short-acting octreotide injection 3 times a day," she explained. (endocrineweb.com)
- The actual octreotide molecule-the active drug that is present in the capsule-is identical to the molecule that is present in the injection. (endocrineweb.com)
- Twenty-two patients with cirrhosis and portal hypertension were randomized to receive a mixed liquid meal (520 kcal) plus a single subcutaneous injection of either placebo or octreotide (200 micrograms). (nih.gov)
- Octreotide may be administered as an injection under the skin (subcutaneous), or as an injection into a muscle (intramuscular) and the dose depends on several factors, including the condition being treated, the particular regimen being used, and the overall health of the patient. (unm.edu)
- Please read this leaflet carefully before you start using Octreotide MaxRx Solution for injection. (nps.org.au)
- This leaflet answers some common questions about Octreotide-MaxRx Injection. (nps.org.au)
- Your doctor has weighed the risks of you using Octreotide-MaxRx Injection against the benefits they expect it will have for you. (nps.org.au)
- By blocking the excess growth hormone, Octreotide-MaxRx Injection can relieve many of these symptoms. (nps.org.au)
- Octreotide-MaxRx Injection is used to relieve symptoms of certain types of cancer such as carcinoid syndrome and VIPoma. (nps.org.au)
- By blocking hormones that are over-produced in these conditions, Octreotide-MaxRx Injection can relieve symptoms such as flushing of the skin and severe diarrhoea. (nps.org.au)
- About the Phase 1 Trial The Phase 1 trial was designed to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of DP1038, a novel formulation of octreotide acetate for intranasal administration, compared to subcutaneous Sandostatin (octreotide acetate) Injection in healthy volunteers. (medindia.net)
- Your search for octreotide injection (generic equivalent to sandostatin) (5 x 1ml) did not match any products. (jandrugs.com)
- Of the 58 participants, 52 were treated with Octreotide-RP, while a control group of 6 participants was given an intravenous injection of an identical dose of octreotide. (pharmiweb.com)
- Current octreotide delivery methods compel patients to choose between painful injections and living with debilitating symptoms especially occurring at the end of injection cycles. (pharmiweb.com)
- The active compound, octreotide , is already commercially available as an injection, marketed by Novartis under the name Sandostatin. (chemistryworld.com)
- Glide Technologies, the development company focused on solid dose formulations of therapeutics and vaccines and non-invasive diagnostics, today announced that it has appointed Albany Molecular Research (Glasgow) Limited (AMRI) to manufacture the company's novel solid dose injection (SDI) formulation of octreotide, for use in a human bioequivalence study to be conducted in Q4 2015. (fiercepharma.com)
- Portal hypertensive rats were allocated into one of four groups (eight rats in each group): vehicle group, octreotide group (100 μg/kg via subcutaneous injection every 12 h), isosorbide dinitrate group (5 mg/kg via gastric gavage every 12 h) and combined treatment group. (portlandpress.com)
- 50% hormone level decrease after octreotide s.c. injection (octreotide test) (OT). (enets.org)
- Description: Subjects received octreotide LAR 30 mg injection via ultrasound-guided IM gluteal injection every 28 days for 3 months. (checkorphan.org)
- On day 1 subjects received 100 μg of octreotide or placebo subcutaneously, three times daily and on day 2, one hour after the fourth injection, gastric emptying, postprandial cholecystokinin (CCK) release, and mouth to caecum transit time (MCTT) were measured. (bmj.com)
- The 2 somatostatin analogs currently recommended by the National Comprehensive Cancer Network for the treatment of gastrointestinal (GI) neuroendocrine tumors (NETs) include octreotide long-acting release (Sandostatin LAR) for injectable suspension and lanreotide (Somatuline Depot) injection for subcutaneous use. (ahdbonline.com)
- Appropriate studies have not been performed on the relationship of age to the effects of the short-acting form of octreotide injection in the pediatric population. (allinahealth.org)
- Appropriate studies performed to date have not demonstrated pediatric-specific problems that would limit the usefulness of the long-acting form of octreotide injection in children 6 to 17 years of age. (allinahealth.org)
- Although appropriate studies on the relationship of age to the effects of octreotide have not been performed in the geriatric population, geriatric-specific problems are not expected to limit the usefulness of octreotide injection in the elderly. (allinahealth.org)
- However, elderly patients are more likely to have age-related kidney, liver, or heart problems, which may require caution and an adjustment in the dose for patients receiving octreotide injection. (allinahealth.org)
- Octreotide injection, 50 mcg/ml (1ml) Inj. (gouv.qc.ca)
- Octreotide injection, 100 mcg/ml (1 ml) Inj. (gouv.qc.ca)
- Octreotide injection, 500 mcg/ml (1 ml) Inj. (gouv.qc.ca)
- Patients not currently receiving octreotide acetate should begin therapy with Sandostatin Injection given subcutaneously in an initial dose of 50 mcg three times daily which may be titrated. (wikidoc.org)
- Patients should be maintained on Sandostatin Injection subcutaneous for at least 2 weeks to determine tolerance to octreotide. (wikidoc.org)
- Patients not currently receiving octreotide acetate should begin therapy with Sandostatin Injection given subcutaneously. (wikidoc.org)
- Thereafter, patients who are considered "responders" to octreotide acetate and who tolerate the drug may be switched to Sandostatin LAR Depot in the dosage regimen as described below (Patients Currently Receiving Sandostatin Injection). (wikidoc.org)
- Because of the need for serum octreotide to reach therapeutically effective levels following initial injection of Sandostatin LAR Depot, carcinoid tumor and VIPoma patients should continue to receive Sandostatin Injection subcutaneously for at least 2 weeks in the same dosage they were taking before the switch. (wikidoc.org)
Sandostatin LAR4
- The long-acting formulation, Sandostatin LAR, is octreotide contained in "microspheres", which allow the drug to be slowly released into the body over a 4-week period. (oncolink.org)
- The side effects of octreotide and their severity depend on how much of the drug is given and which preparation (Sandostatin ® or Sandostatin LAR ® ) is given. (chemocare.com)
- Sandostatin LAR Depot is available as: sterile 6-mL vials in 3 strengths delivering 10 mg, 20 mg, or 30 mg octreotide-free peptide. (rxlist.com)
- To verify that long-acting somatostatin analog octreotide (Sandostatin LAR) depot will extend median survival from 5 months to 8.75 months in patients with locally advanced or metastatic hepatocellular carcinoma with a CLIP score of 3 or more. (knowcancer.com)
Oral octreotide10
- The findings suggest that people who respond well to oral octreotide would be able to avoid the burden of injections if the oral form is approved by the U.S. Food and Drug Administration. (endocrineweb.com)
- After 7 months of treatment at a fixed dose, 65% of participants were considered well controlled on oral octreotide. (endocrineweb.com)
- In addition, 86% who completed the fixed-dose phase chose to participate in a voluntary 6-month extension phase in which they continued using oral octreotide. (endocrineweb.com)
- Notably, 85% of the patients who were well controlled on oral octreotide in the first phase of the study maintained this response up to 13 months in the extension phase. (endocrineweb.com)
- Oral octreotide may not work for me, but it may help 10 other people," Ms Sisco said. (endocrineweb.com)
- The most common adverse events reported with oral octreotide in this study were gastrointestinal, neurological, and musculoskeletal. (endocrineweb.com)
- At the end of the 6-month extension phase, 62% of participants achieved the primary endpoint on oral octreotide. (endocrineweb.com)
- The purpose of this study is to compare the efficacy safety and patient reported outcomes between oral octreotide capsules and injectable somatostatin analogs. (centerwatch.com)
- After Basel, Switzerland-based Roche AG quietly ended its deal with Chiasma for oral octreotide in 2014, Chiasma decided to forge ahead without a partner. (bioworld.com)
- In addition to oral octreotide, Rani has a pipeline of drugs for the treatment of diabetes, osteoporosis, and rheumatoid arthritis, among other diseases. (pharmiweb.com)
Subcutaneously4
- Standard treatment plus 75 micrograms octreotide subcutaneously. (clinicaltrials.gov)
- Patients receive short-acting octreotide subcutaneously three times daily on days 1-21 OR days 1-28. (knowcancer.com)
- Subsequently, octreotide (50 micrograms, three times daily) was administered subcutaneously for 7 days. (diabetesjournals.org)
- Patients not currently receiving octreotide, receive a test dose of octreotide subcutaneously on day 1 during course 1 only and then receive octreotide intramuscularly monthly on day 1. (knowcancer.com)
Effect of Octreotide5
- The antiproliferative effect of Octreotide on metastatic NET is still poorly understood and hasn't been finally evaluated in studies. (egms.de)
- Methods: Using membrane invasion culture system alone or coated with matrigel, we observed the effect of octreotide on blocking migration and invasion of gastric carcinoma cells. (paper.edu.cn)
- Aims -To assess the effect of octreotide, at the clinical dosage used after pancreatic surgery, on gastric emptying in healthy volunteers. (bmj.com)
- The effect of octreotide on gastric motility and emptying rate in patients after pancreatic surgery is unknown. (bmj.com)
- There is thus only an acute effect of octreotide on the perfusion of liver metastases. (eur.nl)
Effects of octreotide6
- There are a number of things you can do to manage the side effects of Octreotide. (oncolink.org)
- OBJECTIVE To evaluate the inhibitory effects of octreotide and diazoxide on insulin secretion in patients with type 1 diabetes and measurable levels of circulating C-peptide. (diabetesjournals.org)
- Differential effects of octreotide on endocrine secretions such as growth hormone (GH) and insulin in healthy volunteers, as well as variable efficacy in the treatment of endocrine tumours, may relate to the distribution of somatostatin receptor subtypes. (ovid.com)
- The wide spectrum of effects of octreotide in humans accounts for adverse effects seen during long term treatment, primarily cholelithiasis. (ovid.com)
- The aim of the present study was to verify the effects of octreotide on hepatic glycogenesis in rats with HFD‑induced obesity. (spandidos-publications.com)
- We have investigated the acute and sustained hemodynamic effects of octreotide on hepatic metastases of midgut carcinoids using contrast-enhanced dynamic magnetic resonance imaging (MRI). (eur.nl)
Receive octreotide4
- If you miss an appointment to receive octreotide, contact your doctor as soon as possible to reschedule your appointment. (medbroadcast.com)
- Following the completion of the core study (Screening, Run-in and RCT phases), eligible patients will be offered to enter the Study Extension phase and receive octreotide capsules until product marketing or study termination. (centerwatch.com)
- Patients then receive octreotide alone for 6-8 courses. (knowcancer.com)
- Patients with documented recurrent tumor progression ineligible for further surgery/radiotherapy were eligible to receive octreotide (30 mg/d, day 1) and everolimus (10 mg/d, days 1-28). (aacrjournals.org)
Growth hormone10
- Octreotide decreases the production of the growth hormone and so treats the symptoms of the condition, however, again it does not cure the tumour. (netdoctor.co.uk)
- Octreotide, sold under the brand name Sandostatin among others, is an octapeptide that mimics natural somatostatin pharmacologically, though it is a more potent inhibitor of growth hormone, glucagon, and insulin than the natural hormone. (wikipedia.org)
- Octreotide provides more potent inhibition of growth hormone, glucagon, and insulin as compared to endogenous somatostatin. (drugs.com)
- Octreotide works by decreasing the amount of growth hormone to normal levels. (webmd.com)
- Octreotide works by reducing the amount of growth hormone that is produced by the body. (mayoclinic.org)
- Subjects were given a GHRH-arginine challenge, a standard test to stimulate growth hormone release, followed by administration of DP1038 or subcutaneous octreotide acetate. (medindia.net)
- Therapeutic octreotide concentrations were achieved, and growth hormone levels were suppressed in this trial by an average of 25%, comparable with SLAR. (apnews.com)
- Octreotide is a synthetic analogue of somatostatin which acts by suppressing basal and stimulated secretion of growth hormone (GH). (drugsupdate.com)
- Octreotide acetate alters the balance between the counter-regulatory hormones, insulin, glucagon and growth hormone, which may result in hypoglycemia or hyperglycemia. (drugsupdate.com)
- Raw Octreotide powder is a more potent inhibitor of growth hormone, glucagon, and insulin than somatostatin. (phcoker.com)
Therapeutic4
- In unresectable metastatic liver lesions positive for somatostatin receptors repeated, transhepatic high doses of 111 In-DTPA-Phe 1 -octreotide show an effective therapeutic outcome. (springer.com)
- This trial achieved all its endpoints confirming that therapeutic doses of octreotide administered via intranasal delivery are well tolerated and supports our goal of providing patients with the first viable non-invasive option for managing their disease," said Joel Martin , Ph.D., President and Chief Executive Officer of Dauntless Pharmaceuticals. (medindia.net)
- Therefore, octreotide may be regarded as a novel therapeutic strategy for HFD‑induced obesity and obesity‑associated metabolic disorders. (spandidos-publications.com)
- The goal of this research is to cyclize octreotide analogues with ⁹⁹[supersript-m]Tc and ¹⁸⁶/¹⁸⁸Re radiometals to be used as diagnostic and therapeutic agents for neuroendocrine tumors, respectively. (umsystem.edu)
Peptide7
- Octreotide can also be labeled with a variety of radionuclides, such as yttrium-90 or lutetium-177, to enable peptide receptor radionuclide therapy (PRRT) for the treatment of unresectable neuroendocrine tumours. (wikipedia.org)
- By virtue of these pharmacological actions, octreotide acetate has been used to treat the symptoms associated with metastatic carcinoid tumors (flushing and diarrhea), and Vasoactive Intestinal Peptide (VIP) secreting adenomas (watery diarrhea). (nih.gov)
- Octreotide is used to treat severe watery diarrhea and sudden reddening of the face and neck caused by certain types of tumors (e.g., carcinoid tumors , vasoactive intestinal peptide tumors) that are found usually in the intestines and pancreas . (webmd.com)
- Octreotide is FDA approved for the management of diarrhea and flushing, as part of carcinoid syndrome caused by carcinoid tumor or vasoactive intestinal peptide (VIP) secreting adenomas. (unm.edu)
- About DP1038 Octreotide is a synthetic peptide analog of naturally occurring somatostatin, with similar pharmacological effects but longer duration of action. (medindia.net)
- The purpose of the present study was to characterize the in vivo release kinetics of octreotide acetate from microsphere formulations designed to minimize peptide acylation and improve drug stability. (springer.com)
- 12 13 Octreotide inhibits secretion of gastrointestinal hormones such as cholecystokinin (CCK), gastrin, pancreatic polypeptide, motilin, secretin, glucose dependent insulinotropic peptide (GIP), vasoactive intestinal polypeptide (VIP), insulin, and glucagon, and impairs gastric and pancreatic secretion and gall bladder motility. (bmj.com)
Starting octreotide treatment1
- Before starting octreotide treatment, make sure you tell your doctor about any other medications you are taking (including prescription, over-the-counter, vitamins, herbal remedies, etc. (chemocare.com)
Somatostatin analog octreotide2
- Smith S, Anthony L, Roberts LJ, Oates JA, Pincus T. Resolution of Musculoskeletal Symptoms in the Carcinoid Syndrome after Treatment with the Somatostatin Analog Octreotide. (annals.org)
- Purpose: To report on the efficacy of the somatostatin analog octreotide long-acting repeatable (LAR), in the treatment of uveitic chronic macular edema (CME). (eur.nl)
Secretion6
- People with diabetes mellitus might need less insulin or oral antidiabetics when treated with octreotide, as it inhibits glucagon secretion more strongly and for a longer time span than insulin secretion. (wikipedia.org)
- Single doses of octreotide acetate have been shown to inhibit gallbladder contractility and to decrease bile secretion in normal volunteers. (nih.gov)
- Octreotide acetate suppresses secretion of thyroid stimulating hormone (TSH). (nih.gov)
- Since this scintigraphy demonstrated the presence of somatostatin receptors, empiric treatment with the somatostatin analogue octreotide was initiated in an attempt to stabilize catecholamine secretion prior to attempted surgical resection. (spandidos-publications.com)
- Treatment of pain in chronic pancreatitis by inhibition of pancreatic secretion with octreotide. (bmj.com)
- Octreotide acetate also suppresses secretion of thyroid stimulating hormone, which may result in hypothyroidism. (drugsupdate.com)
Analog6
- Octreotide, being a somatostatin analog, inhibits the release of GH from the pituitary gland through a process normally involved in negative feedback. (wikipedia.org)
- MYCAPSSA delayed release capsules contain octreotide acetate, a somatostatin analog. (rxlist.com)
- Octreotide is a somatostatin analog that is known to suppress numerous hormones including insulin. (clinicaltrials.gov)
- Octreotide (Sandostatin), a somatostatin analog, has a wide range of uses in the management of cancer patients. (cancernetwork.com)
- Octreotide acetate is a longer acting synthetic octapeptide analog of naturally occurring somatostatin. (worldbid.com)
- The acute symptoms are inhibited by the long-acting octapeptide analog of somatostatin, octreotide (SMS-201-995) (2). (annals.org)
Form of octreotide2
- This medication is a long-acting form of octreotide. (kaiserpermanente.org)
- You must respond well to the short-acting form of octreotide before switching to this medication. (kaiserpermanente.org)
Role of octreotide2
- Additional data may be necessary to further define the role of octreotide in this condition. (drugs.com)
- In an established guinea pig model, the role of octreotide in lymphatic function was examined. (lymphedemapeople.com)
Efficacy of octreotide3
- Recent case reports and one prospective study in healthy volunteers have demonstrated the safety and efficacy of octreotide administration for the treatment of sulfonylurea induced hypoglycemia. (clinicaltrials.gov)
- The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study. (diabetesjournals.org)
- To evaluate the efficacy of octreotide in the treatment of pituitary thyroid-stimulating hormone (TSH)-secreting adenomas. (annals.org)
Administration of octreotide6
- Administration of octreotide was performed every 28 days (± 4 days) starting on Cycle 1, Day 1. (clinicaltrials.gov)
- Based largely on the results of these studies some experts in field of toxicology have argued that administration of octreotide be standard therapy for all patients with recurrent hypoglycemic episodes who are known to be taking sulfonylureas. (clinicaltrials.gov)
- A Sub-study, in selected sites, would allow patients with in-adequate biochemical control on octreotide capsules during the Run-in Phase to enter a Combination phase and receive co-administration of octreotide capsules with cabergoline tablets for a total of 36 weeks. (centerwatch.com)
- We speculate that liver cirrhosis can be a cause of intestinal lymphangiectasia and administration of octreotide should be considered for patients with intestinal lymphangiectasia whose clinical and biochemical abnormalities do not respond to a low-fat diet. (lymphedemapeople.com)
- The present study was undertaken to evaluate the effect of long-term administration of octreotide and isosorbide dinitrate on haemodynamics in rats with portal vein stenosis. (portlandpress.com)
- CONCLUSION: Thrice-daily was more effective than twice-daily administration of octreotide, and dose increments above 100 micrograms thrice daily did not confer additional benefit. (garvan.org.au)
0.053
- 0.05), whereas octreotide had no such effect. (diabetesjournals.org)
- 0.05), octreotide being the more potent in this respect. (diabetesjournals.org)
- MEASUREMENTS AND MAIN RESULTS: Octreotide, 100 micrograms administered twice or thrice daily, significantly reduced mean 12-hour and nadir GH (P less than 0.01), IGF-1 (P less than 0.05), and hand volume (P less than 0.05). (garvan.org.au)
Neuroendocrine tumours3
- An octreotide scan may be used to locate suspected primary neuroendocrine tumours (NET) or for follow-up or staging after treatment. (wikipedia.org)
- The aim of this study is to evaluate the effectiveness of 111 In-DTPA-Phe 1 -octreotide infusions after selective catheterization of the hepatic artery in inoperable metastasised liver, sst 2 receptor-positive neuroendocrine tumours due to the effect of 111 In Auger electron emission, minimising in parallel the toxicity of non-target tissue. (springer.com)
- Kaltsas GA, Stefanidou Z, Papadogias D, Grossmann A. Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogue octreotide. (springer.com)
Injectable3
- Octreotide is currently only approved as an injectable formulation. (endocrineweb.com)
- Injectable somatostatin analogs (including octreotide) typically are given once a month. (endocrineweb.com)
- Octreotide capsule is a novel, orally-administered formulation of the commercially-available injectable drug octreotide. (centerwatch.com)
Intervention1
- Octreotide intervention restored these alterations. (spandidos-publications.com)
Cyclic3
- Octreotide is the acetate salt of a cyclic octapeptide. (rxlist.com)
- Octreotide belongs to digestive system drugs, which is an artificially synthetic cyclic octapeptide compound, and is a homolog of natural somatostatin. (chemicalbook.com)
- A unique optimization of a Waters system for bioanalysis, from sample preparation to UPLC chromatography to tandem quadrupole MS, enables the determination and quantification of octreotide, a cyclic octapeptide that is used for treating cancer patients, at the 5 pg/mL level. (selectscience.net)
Micrograms3
- In Part 1 of the study, each of 12 subjects received three doses of DP1038 plus 100 micrograms of subcutaneous octreotide acetate in a randomized 4 x 4 Latin square design. (medindia.net)
- In Part 2 of the study, a single dose of DP1038, which was selected to exhibit a similar pharmacokinetic profile to subcutaneous octreotide acetate, was evaluated in 20 subjects in a cross-over design to compare the pharmacodynamic effect to 100 micrograms of subcutaneous octreotide acetate. (medindia.net)
- INTERVENTIONS: Eight patients (group 1) were treated with 100, 250, and 500 micrograms twice daily of octreotide, then switched to 333 micrograms three times daily, whereas 11 patients (group 2) were treated with 100, 200, 300, and 500 micrograms three times daily. (garvan.org.au)
Hepatic5
- This study investigates whether octreotide prevents the increases in hepatic flow and portal pressure that follow the ingestion of a meal in patients with cirrhosis. (nih.gov)
- In conclusion, in patients with cirrhosis and portal hypertension, octreotide prevents the postprandial increase in hepatic blood flow, and consequently also in portal pressure. (nih.gov)
- Hepatic metabolism of octreotide is extensive (30 to 40%) and about 11 to 20% of the dose is excreted unchanged in the urine. (ovid.com)
- However, whether octreotide affects hepatic glycogenesis is unknown. (spandidos-publications.com)
- In conclusion, the results indicate that octreotide improved hepatic glycogenesis and decreased FPG concentration in rats with HFD‑induced obesity. (spandidos-publications.com)
Formulation4
- This was afrank, interactive forum reviewing new data on octreotide and the long-actingrelease (LAR) formulation, octreotide LAR depot, to determine its future inresearch. (cancernetwork.com)
- on the development of specialty therapeutics, today announced positive results from its two-part, Phase 1 pharmacokinetic/pharmacodynamic study evaluating DP1038, a novel formulation of octreotide acetate for intranasal administration. (medindia.net)
- David Stevens, Senior Director and Site Head of AMRI Glasgow, commented, 'AMRI is thrilled to work with Glide on the GMP manufacture of their octreotide formulation. (fiercepharma.com)
- This study will assess the pharmacokinetic profile, safety and tolerability of an octreotide extended long-acting formulation after a single dose in humans. (bioportfolio.com)
Intramuscularly3
- Everolimus was administered in accordance with a 10-mg daily dosing regimen (two 5-mg tablets) in conjunction with octreotide 30 mg intramuscularly (i.m.) every 28 days. (clinicaltrials.gov)
- Patients receive oral vatalanib once daily on days 1- 28 and octreotide* intramuscularly or IV on day 1. (clinicaltrials.gov)
- Comets E, Mentre F, Kawai R, Nimmerfall F, Marbach P, Vonderscher J. Modeling the kinetics of release of octreotide from long-acting formulations injected intramuscularly in rabbits. (springer.com)
Treatment with octreotide acetate1
- Cardiac conduction abnormalities have also occurred during treatment with Octreotide acetate. (drugsupdate.com)
Depot4
- Open Label - Patients who had progressive disease in this arm, can move to the open label Everolimus + depot octreotide by choice. (clinicaltrials.gov)
- Scott Wadler and Babu Zachariah discuss potential researchavenues with octreotide LAR depot in the field of therapy-induced diarrhea. (cancernetwork.com)
- Henotes the value of octreotide in the treatment of National Cancer Institute(NCI) Common Toxicity Criteria grade 3 and 4 diarrheas but elaborates on theemerging role of prophylactic octreotide (particularly the use and research onoctreotide LAR depot). (cancernetwork.com)
- He reports on two small studies thatdemonstrated potential benefit of therapy with octreotide but emphasizes andoutlines two cooperative group studies (by the Radiation Therapy Oncology Groupand the North Central Cancer Treatment Group) that would systematically evaluatethe value of prophylactic octreotide LAR depot. (cancernetwork.com)
Intestinal9
- medical citation needed] Octreotide can reduce the intestinal reabsorption of ciclosporin, possibly making it necessary to increase the dose. (wikipedia.org)
- Octreotide seems to work by reducing gastric and intestinal secretions. (medhelp.org)
- Octreotide in intestinal lymphangiectasia: lack of a clinical response and failure to alter lymphatic function in a guinea pig model. (lymphedemapeople.com)
- A small number of recent reports advocate the use of octreotide in intestinal lymphangiectasia. (lymphedemapeople.com)
- although octreotide can alter splanchnic blood flow and intestinal motility, its actions on lymphatic function has never been investigated. (lymphedemapeople.com)
- A case of a patient with intestinal lymphangiectasia who required a shunt procedure after failing medium chain triglycerides and octreotide therapy is presented. (lymphedemapeople.com)
- During the management of this case, all existing literature on intestinal lymphangiectasia and all the known actions of octreotide were reviewed. (lymphedemapeople.com)
- Because some of the case reports suggested that octreotide may improve the clinical course of intestinal lymphangiectasia by altering lymphatic function, a series of experiments were undertaken to assess this. (lymphedemapeople.com)
- Primary intestinal lymphangiectasia successfully treated with octreotide. (lymphedemapeople.com)
Diarrhea5
- Octreotide has also been used off-label for the treatment of severe, refractory diarrhea from other causes. (medhelp.org)
- By decreasing watery diarrhea , octreotide helps to reduce the loss of body fluids and minerals . (webmd.com)
- Octreotide may help control symptoms, such as diarrhea, caused by the tumor. (clinicaltrials.gov)
- Octreotide mimics natural somatostatin to control the overproduction of certain hormones and to control symptoms such as diarrhea or flushing in patients with a carcinoid tumor or VIP. (unm.edu)
- Octreotide was originally used as a opiod antagonist and is still used off label as a second/third line therapy for diarrhea from opiod withdrawal because of antidiarrheal properties. (wikem.org)
Scintigraphy4
- An octreotide scan is a type of SPECT scintigraphy used to find carcinoid, pancreatic neuroendocrine tumors, and to localize sarcoidosis. (wikipedia.org)
- An octreotide scan, also known as somatostatin receptor scintigraphy, is a test used to check the body for the presence of neuroendocrine tumor cells. (oncolink.org)
- Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. (springer.com)
- Internalization of radiolabelled [DTPA°]octreotide and [DOTA°, Tyr 3 ]octreotide: peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy. (springer.com)
Symptoms6
- Octreotide may control your symptoms, but it will not cure your condition. (medlineplus.gov)
- If you stop taking octreotide, your symptoms may return. (medlineplus.gov)
- Octreotide only relieves the symptoms of these hormone-producing tumours, it does not cure the tumour. (netdoctor.co.uk)
- Octreotide works to reduce the production of these hormones and thereby decrease the symptoms. (oncolink.org)
- We describe three patients with the carcinoid syndrome in whom treatment with octreotide was followed by resolution of their musculoskeletal symptoms. (annals.org)
- A 58 year-old woman complaining of severe neurological symptoms caused by a giant prolactinoma, relapsing after surgery and not-responding to dopamine-agonists and octreotide LAR treatment, underwent four cycles of PRRT with 111-Indium-DTPA-octreotide with remarkable tumour shrinkage and a significant improvement in clinical conditions. (springer.com)
Clinical9
- Clinical experience suggests the benefit of octreotide in preventing carcinoid crisis prior to invasive procedures in patients with neuroendocrine tumors [Oberg 2004] . (drugs.com)
- We report the case of a 54-year-old female patient affected by a suspected pituitary macroadenoma with severe visual field defects, who experienced a significant clinical and visual improvement during short-term octreotide therapy, contrasting with the lack of neuroradiological evidence for tumor shrinkage. (nih.gov)
- The Phase I clinical study of Octreotide-RP was conducted in Australia with 58 healthy adult volunteers. (pharmiweb.com)
- The human results with octreotide are compelling and demonstrate the safety and efficacy of the RaniPill™, a major milestone for Rani but also a first for the industry," added Dennis Ausiello, M.D., Physician-in-Chief, Emeritus at Massachusetts General Hospital and Jackson Distinguished Professor of Clinical Medicine at Harvard Medical School, and Rani Therapeutics board member. (pharmiweb.com)
- Under the terms of the manufacturing agreement, AMRI will install the clinical production line developed by Glide into its GMP facility, and will produce sterile octreotide solid doses for clinical study. (fiercepharma.com)
- In conclusion, in this case, octreotide failed to induce a clinical response and laboratory studies showed that octreotide did not alter lymphatic function. (lymphedemapeople.com)
- Thus, the mechanisms by which octreotide induced clinical responses in the cases reported elsewhere in the literature remain unclear, but the present study suggests that it does not appear to act via increasing lymphatic pumping. (lymphedemapeople.com)
- Octreotide administered at the clinical dosage for pancreatic surgery accelerates gastric emptying, mainly by shortening the lag time. (bmj.com)
- Clinical pharmacokinetics of octreotide. (wikem.org)
Doses1
- Improved survival with higher doses of octreotide long-acting release in gastroenteropancreatic neuroendocrine tumors. (bioportfolio.com)
Lanreotide4
- The purpose of this study is to understand how people with neuroendocrine tumors respond to treatment with lanreotide after having received treatment with octreotide. (clinicaltrials.gov)
- To estimate the costs to payers associated with 30-mg octreotide LAR and 120-mg lanreotide treatment among patients with metastatic GI-NETs. (ahdbonline.com)
- Over a 5-year horizon, the costs of adverse events and administration accounted for 0.72% of the total cost for octreotide LAR and 0.51% of the total cost for lanreotide. (ahdbonline.com)
- For the management of metastatic GI-NETs, the cost to payers of treatment with 30-mg octreotide LAR is considerably lower than with 120-mg lanreotide over 1-, 3-, and 5-year horizons. (ahdbonline.com)
Carcinoid tumors1
- Seven patients with the carcinoid syndrome and metastasized midgut carcinoid tumors underwent functional dynamic multi-phase gadolinium-enhanced MRI of selected liver metastases at baseline and 60 min after the subcutaneous (s.c.) administration of 100 μg octreotide, and also after 3 months with three times daily (t.i.d.) 100 μg octreotide s.c. (eur.nl)
Pancreatic4
- Octreotide scanning is reported to have a sensitivity between 75% and 100% for detecting pancreatic neuroendocrine tumors. (wikipedia.org)
- Background -Octreotide is used in many centres to prevent complications after pancreatic surgery. (bmj.com)
- 5-7 A number of recent randomised, placebo controlled multicentre trials showed that octreotide could reduce postoperative complications when administered to patients undergoing pancreatic surgery. (bmj.com)
- 8-11 Although mortality was not affected in these studies, perioperative treatment with octreotide seems to be indicated in pancreatic surgery. (bmj.com)
Hormones2
- Octreotide mimics the action of natural sandostatin and so decreases the production of these types of hormones. (netdoctor.co.uk)
- Diazoxide inhibits hormonal release directly on the beta-cells, whereas octreotide exerts its effect indirectly, presumably by multiple actions on insulin sensitivity and insulin-releasing hormones. (diabetesjournals.org)
Gastrointestinal1
- Octreotide helps in management of the fistula by reducing gastrointestinal secretions and inhibiting gastrointestinal motility, thus controlling and reducing its output. (wikipedia.org)
Microspheres1
- The octreotide is uniformly distributed within the microspheres which are made of a biodegradable glucose star polymer, D,L-lactic and glycolic acids copolymer. (rxlist.com)
Short-acting oct1
- Short-acting octreotide is injected under the skin ( subcutaneous ) of the hip, thigh, or abdomen 2 to 4 times daily. (medbroadcast.com)
Action of octreotide2
- The duration of action of octreotide acetate is variable but extends up to 12 hours depending upon the type of tumor. (nih.gov)
- Antifibrotic action of octreotide has been reported in pulmonary fibrosis. (bioportfolio.com)
Profile of octreotide1
- Results from the study indicate that MTD201 produces a safe and effective sustained-release profile of octreotide, supporting a once-monthly treatment interval, as is indicated for SLAR. (apnews.com)
Safety and tolerability1
- The Phase I study successfully achieved both its primary and secondary endpoints, demonstrating the safety and tolerability of Octreotide-RP, the RaniPill™ loaded with octreotide, and high oral bioavailability of the biologic drug. (pharmiweb.com)
Suggest that octreotide2
- CONCLUSIONS: Our results suggest that octreotide treatment in euthyroid patients may retard progression of advanced DR and may delay the time to laser surgery. (diabetesjournals.org)
- These results also suggest that octreotide, a molecule with different signalling pathways, was able as doxorubicin to generate a p53 breakdown product. (portlandpress.com)
Injections of octreotide2
- Nude mice implanted orthotopically with SGC-7901 human stomach carcinoma were given injections of octreotide for 8 weeks. (paper.edu.cn)
- Last week i stopped taking Cabergoline and started on daily injections of Octreotide. (dickymoo.com)
Tumour6
- Octreotide is also used to treat thyrotrophic adenomas, which are a different type of tumour affecting the pituitary gland. (netdoctor.co.uk)
- Octreotide is used when levels of TSH still remain too high following surgery or radiotherapy to treat the pituitary tumour, in the interim period until radiotherapy becomes effective, or in people for whom surgery is inappropriate. (netdoctor.co.uk)
- In a minority of patients complete resistance to octreotide was observed and was not always related to the absence of somatostatin receptors in the tumour. (ovid.com)
- Beside the symptomatic treatment a number of cases of partial tumour regression with octreotide administered with or without other treatment modalities have been reported in the literature [ Ref. 1] . (egms.de)
- The chemotherapeutic drug doxorubicin and the anti-proliferative long-acting somatostatin analogue octreotide, both used in cancer treatment, have been shown to increase the expression of the p53 tumour suppressor protein. (portlandpress.com)
- Recent advances in receptor-mediated tumour imaging have resulted in the development of a new somatostatin analogue, DOTA-dPhe(1)-Tyr(3)-octreotide. (eurekamag.com)
Insulin3
- Octreotide is thought to block the elevated insulin levels that are a result of both the sulfonlyureas and dextrose. (clinicaltrials.gov)
- Octreotide blunted the postprandial increase in serum insulin and glucagon levels observed in the placebo group. (nih.gov)
- Octreotide acts by inhibiting the release of insulin from the pancreas. (gouv.qc.ca)
Analogs1
- Octreotide is in a class of medication called somatostatin analogs, which currently are only available for use as injections. (endocrineweb.com)